Scutellarin: Pharmacological Effects and Therapeutic Mechanisms in Chronic Diseases

Overview

Journal Front Pharmacol

Date 2024 Nov 22

PMID 39575387

Authors

Shanshan Nie

Shan Zhang

Ruipeng Wu

Yuhang Zhao

Yongxia Wang

Xinlu Wang

Mingjun Zhu

Peng Huang

Affiliations

Soon will be listed here.

Abstract

Scutellarin (SCU), a flavonoid glucuronide derived from and , exhibits broad pharmacological effects with promising therapeutic potential in treating various chronic diseases. It has demonstrated efficacy in modulating multiple biological pathways, including antioxidant, anti-inflammatory, anti-apoptotic, and vasodilatory mechanisms. These protective roles make SCU a valuable compound in treating chronic diseases such as cerebrovascular diseases, cardiovascular diseases, neurodegenerative disorders, and metabolic diseases. Despite its multi-targeted effects, SCU faces challenges such as low bioavailability and limited clinical data, which hinder its widespread therapeutic application. Current research supports its potential to prevent oxidative stress, reduce inflammatory responses, and enhance cell survival in cells and rats. However, more comprehensive studies are required to clarify its molecular mechanisms and to develop strategies that enhance its bioavailability for clinical use. SCU could emerge as a potent therapeutic agent for the treatment of chronic diseases with complex pathophysiological mechanisms. This review examines the current literature on Scutellarin to provide a comprehensive understanding of its pharmacological activity, mechanisms of action, and therapeutic potential in treating chronic diseases.

References

Jiang D, Li Q, Yang J, Perelman J, Kolosov V, Zhou X . Scutellarin attenuates human-neutrophil-elastase-induced mucus production by inhibiting the PKC-ERK signaling pathway in vitro and in vivo. Am J Chin Med. 2011; 39(6):1193-206. DOI: 10.1142/S0192415X11009494. View

Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T . Management of locally advanced non-small cell lung cancer: State of the art and future directions. Cancer Commun (Lond). 2023; 44(1):23-46. PMC: 10794016. DOI: 10.1002/cac2.12505. View

Xie W, Zhu T, Dong X, Nan F, Meng X, Zhou P . HMGB1-triggered inflammation inhibition of notoginseng leaf triterpenes against cerebral ischemia and reperfusion injury via MAPK and NF-κB signaling pathways. Biomolecules. 2019; 9(10). PMC: 6843331. DOI: 10.3390/biom9100512. View

Zeng Y, Cui Y, Gu J, Liang C, Zhou X . Scutellarin Mitigates Aβ-Induced Neurotoxicity and Improves Behavior Impairments in AD Mice. Molecules. 2018; 23(4). PMC: 6017345. DOI: 10.3390/molecules23040869. View

Pawluk H, Tafelska-Kaczmarek A, Soponska M, Porzych M, Modrzejewska M, Pawluk M . The Influence of Oxidative Stress Markers in Patients with Ischemic Stroke. Biomolecules. 2024; 14(9). PMC: 11430825. DOI: 10.3390/biom14091130. View

Guo L, Guan Z, Huang Y, Wang Y, Shi J . The neurotoxicity of β-amyloid peptide toward rat brain is associated with enhanced oxidative stress, inflammation and apoptosis, all of which can be attenuated by scutellarin. Exp Toxicol Pathol. 2012; 65(5):579-84. DOI: 10.1016/j.etp.2012.05.003. View

Huang H, Geng Q, Yao H, Shen Z, Wu Z, Miao X . Protective effect of scutellarin on myocardial infarction induced by isoprenaline in rats. Iran J Basic Med Sci. 2018; 21(3):267-276. PMC: 5817170. DOI: 10.22038/ijbms.2018.26110.6415. View

Liu F, Li L, Lu W, Ding Z, Huang W, Li Y . Scutellarin ameliorates cartilage degeneration in osteoarthritis by inhibiting the Wnt/β-catenin and MAPK signaling pathways. Int Immunopharmacol. 2019; 78:105954. DOI: 10.1016/j.intimp.2019.105954. View

Shin J, Kweon K, Kim D, Kim P, Jeon T, Maeng S . Scutellarin Ameliorates Learning and Memory Deficit via Suppressing β-Amyloid Formation and Microglial Activation in Rats with Chronic Cerebral Hypoperfusion. Am J Chin Med. 2018; 46(6):1203-1223. DOI: 10.1142/S0192415X18500635. View

10.

Li Y, Lui K, Zhou B . Reassessing endothelial-to-mesenchymal transition in cardiovascular diseases. Nat Rev Cardiol. 2018; 15(8):445-456. DOI: 10.1038/s41569-018-0023-y. View

11.

Xu L, Chen R, Zhang X, Zhu Y, Ma X, Sun G . Scutellarin protects against diabetic cardiomyopathy via inhibiting oxidative stress and inflammatory response in mice. Ann Palliat Med. 2021; 10(3):2481-2493. DOI: 10.21037/apm-19-516. View

12.

Xi J, Rong Y, Zhao Z, Huang Y, Wang P, Luan H . Scutellarin ameliorates high glucose-induced vascular endothelial cells injury by activating PINK1/Parkin-mediated mitophagy. J Ethnopharmacol. 2021; 271:113855. DOI: 10.1016/j.jep.2021.113855. View

13.

Shahmohammadi A, Golchoobian R, Mirahmadi S, Rousta A, Ansari F, Sharayeli M . Scutellarin alleviates lipopolysaccharide-provoked septic nephrotoxicity via attenuation of inflammatory and oxidative events and mitochondrial dysfunction. Immunopharmacol Immunotoxicol. 2022; 45(3):295-303. DOI: 10.1080/08923973.2022.2141644. View

14.

Dong Y, Wang B, Du M, Zhu B, Cui K, Li K . Targeting Epsins to Inhibit Fibroblast Growth Factor Signaling While Potentiating Transforming Growth Factor-β Signaling Constrains Endothelial-to-Mesenchymal Transition in Atherosclerosis. Circulation. 2023; 147(8):669-685. PMC: 10136057. DOI: 10.1161/CIRCULATIONAHA.122.063075. View

15.

Li F, Wang S, Niu M . Scutellarin Inhibits the Growth and EMT of Gastric Cancer Cells through Regulating PTEN/PI3K Pathway. Biol Pharm Bull. 2021; 44(6):780-788. DOI: 10.1248/bpb.b20-00822. View

16.

Dai J, Li C, Zhao L, Guan C, Yang C, Zhang N . Scutellarin protects the kidney from ischemia/reperfusion injury by targeting Nrf2. Nephrology (Carlton). 2022; 27(8):690-700. DOI: 10.1111/nep.14069. View

17.

Yang N, Zhao Y, Wang Z, Liu Y, Zhang Y . Scutellarin suppresses growth and causes apoptosis of human colorectal cancer cells by regulating the p53 pathway. Mol Med Rep. 2016; 15(2):929-935. DOI: 10.3892/mmr.2016.6081. View

18.

Yue T, Shi Y, Luo S, Weng J, Wu Y, Zheng X . The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Front Immunol. 2022; 13:1055087. PMC: 9792618. DOI: 10.3389/fimmu.2022.1055087. View

19.

Zhang H, Hu X, Wang L, Xu S, Zeng F . Protective effects of scutellarin against cerebral ischemia in rats: evidence for inhibition of the apoptosis-inducing factor pathway. Planta Med. 2008; 75(2):121-6. DOI: 10.1055/s-0028-1088368. View

20.

Marshall J, Leligdowicz A . Gaps and opportunities in sepsis translational research. EBioMedicine. 2022; 86:104387. PMC: 9783171. DOI: 10.1016/j.ebiom.2022.104387. View